Oncology ASCO 2024 - Paul Burton For Amgen, ASCO 2024 was all about lung cancer, with encouraging data in both non-small cell and small cell lung cancer.
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
